Dako, an Agilent Technologies Company, has launched instant quality in situ hybridization (IQISH) technology in the US, to lessen cancer evaluation turnaround time.
IQISH technology, based on Dako's fast IQISH hybridization buffer chemistry, reduces the evaluation time from two days to three and a half hours, facilitating quick initiation of the targeted cancer treatments.
Agilent senior vice president and Dako CEO Lars Holmkvist said, "Every second counts when waiting for test results that will indicate how to treat your cancer most effectively."
A FDA approved fluorescence in situ hybridization (FISH) assay, HER2 IQFISH pharmDx that is based in IQISH technology, is now available in the US.
The HER2 IQFISH pharmDx assay aids in detecting HER2 gene status to evaluate breast cancer.
